Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sanofi ( (SNY) ) is now available.
On October 8, 2025, Sanofi announced that its investigational therapy AlphaMedixTM (212Pb-DOTAMTATE) met all primary efficacy endpoints in a phase 2 study for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study showed clinically meaningful benefits in both PRRT-naïve and PRRT-exposed patients, with a manageable safety profile. These results highlight the potential of Targeted Alpha Therapy with lead-212 as a new treatment option, reinforcing Sanofi’s commitment to innovative cancer therapies. The findings will be discussed with health authorities and presented at the 2025 European Society for Medical Oncology Congress.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives by developing medicines and vaccines. They focus on leveraging their understanding of the immune system to create innovative treatments, aiming to address urgent healthcare challenges globally. Sanofi is listed on EURONEXT and NASDAQ.
Average Trading Volume: 3,049,572
Technical Sentiment Signal: Buy
Current Market Cap: $119.2B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.